Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.
Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.
Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
The U.S. Patent and Trademark Office granted Emmanuelle Charpentier — co-founder of ERS Genomics — the University of California, and the University of Vienna their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.